Press release
Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options
SAN DIEGO, July 25, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences
About this update from Illumina, Inc.
[{"type":"text","content":"SAN DIEGO, July 25, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the pioneers of Decision Medicine™, today announced a strategic partnership to make Pillar's suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products. The agreement will result in an unprecedented offering of complementary next-generation sequencing solutions that will enhance the efficiency, accuracy, and cost-effectiveness of oncology testing through advanced sequencing techniques, improving patient access to personalized cancer treatment options.\n\"We are proud to partner with Pillar to provide products that will improve care for patients with advanced and high-risk cancer,\" said Phil Febbo, chief medical officer of Illumina. \"By leveraging Pillar's targeted sequencing technology alongside Illumina's state-of-the-art sequencing and bioinformatics solutions, we will enable rapid and focused genomic profiling of tumors, which is essential to facilitate personalized therapy in healthcare systems across the globe.\"\nPillar's targeted assays help oncologists and researchers identify mutations that drive tumor growth. This knowledge is pivotal in making informed decisions about cancer treatment. By gaining an understanding of the genomic landscape of the tumor, clinicians can tailor treatment options such as targeted therapies and immunotherapies to suit each patient's needs. This personalized approach has the potential to result in more effective and precise interventions.\n\"Pillar Biosciences is committed to enabling global access to our high-value genomic profiling assays to empower better-informed precision patient treatment,\" said Randy Pritchard, CEO of Pillar Biosciences. \"This agreement will facilitate seamless integration between Pillar Biosciences assays and Illumina sequencers, delivering a streamlined workflow and complementary product offerings and leading to faster turnaround times for patients.\"\nPillar's suite of oncology assays can be used on any of Illumina's sequencers. Assay offering will depend on the region. Commercial availability of Pillar's assays through Illumina is set to begin this month.\nUse of forward-looking statementsThis release may contain forward-looking statements that inv...